Hidenori Suzuki1, Masami Nishio2, Nobuhiro Hanai3, Hitoshi Hirakawa3, Tsuneo Tamaki4, Yasuhisa Hasegawa3. 1. Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan hi.suzuki@aichi-cc.jp. 2. Department of Radiology, Nagoya PET Imaging Center, Nagoya, Japan. 3. Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan. 4. East Nagoya Imaging Diagnosis, Nagoya, Japan.
Abstract
AIM: High [18F]-2-fluorodeoxyglucose (18F-FDG) -uptake of primary tumor, assessed by pretreatment positron emission tomography combined computed tomography (PET/CT), has indicated poor overall survival (OS) in head and neck cancer (HNC).We investigated the correlation between 18F-FDG-uptake and in vitro chemosensitivity of cisplatin using histoculture drug response assay in HNC. PATIENTS AND METHODS: Twenty-eight patients were evaluated. The maximum standardized uptake value (SUVmax) and inhibition index (I.I.) cisplatin were calculated as 18F-FDG-uptake and in vitro chemosensitivity of cisplatin. RESULTS: Each SUVmax10.5 or I.I.cisplatin<50 could significantly differentiate shorter survival group by OS analyses. I.I.cisplatin of patients with SUVmax≥10.5 was significantly greater. In 19 patients with SUVmax≥10.5, those who received treatment with cisplatin-based chemotherapy exhibited a significant correlation with longer OS. CONCLUSION: Cisplatin hasthe potential to improve OS for HNC patients that were predicted as shorter OS by 18F-FDG-PET/CT. Copyright
AIM: High [18F]-2-fluorodeoxyglucose (18F-FDG) -uptake of primary tumor, assessed by pretreatment positron emission tomography combined computed tomography (PET/CT), has indicated poor overall survival (OS) in head and neck cancer (HNC).We investigated the correlation between 18F-FDG-uptake and in vitro chemosensitivity of cisplatin using histoculture drug response assay in HNC. PATIENTS AND METHODS: Twenty-eight patients were evaluated. The maximum standardized uptake value (SUVmax) and inhibition index (I.I.) cisplatin were calculated as 18F-FDG-uptake and in vitro chemosensitivity of cisplatin. RESULTS: Each SUVmax10.5 or I.I.cisplatin<50 could significantly differentiate shorter survival group by OS analyses. I.I.cisplatin of patients with SUVmax≥10.5 was significantly greater. In 19 patients with SUVmax≥10.5, those who received treatment with cisplatin-based chemotherapy exhibited a significant correlation with longer OS. CONCLUSION:Cisplatin hasthe potential to improve OS for HNC patients that were predicted as shorter OS by 18F-FDG-PET/CT. Copyright